Autonomous parvoviruses are small, single strand DNA construct unexpectedly showed constitutive expression in viruses which preferentially replicate in transformed and transiently transfected cells, as indicated by efficient excitumor cells, causing cell death by expression of the cytosion and amplification of viral replicative form (RF) DNA. toxic nonstructural protein, NS1. Several parvoviruses of This was apparently due to self-stimulatory transcriptional the rodent group, including LuIII, efficiently infect human transactivation by NS1. This problem was overcome by transformed cell lines. The potential for systemic use of cotransfection with a plasmid expressing a chimera of the these viruses in targeting metastases might be enhanced repressor of the tetracycline operon with a KRAB transif NS1 expression and viral replication could be controlled repression domain. These conditions allowed efficient conby an innocuous drug such as tetracycline. We therefore trol of transcription and RF amplification by the tetracycline substituted prokaryotic tetracycline operator sequences for derivative, doxycycline. These observations form a basis part of P4 of LuIII, the promoter responsible for transcripfor developing a therapeutic agent based on a drugtion of the mRNAs for nonstructural proteins. The resulting controlled parvovirus.
Introduction
Parvoviruses are small, icosahedral viruses containing a single strand DNA genome of approximately 5 kb which replicates via double strand linear replicative forms (RF) in the nuclei of infected cells. 1 These viruses can be classified as dependoviruses (adeno-associated viruses), requiring a helper virus for replication, or as autonomous. 1, 2 The latter occur widely, require proliferating cells and replicate efficiently in, and preferentially kill, malignantly transformed cells. 3 Cell killing appears to be due largely to the cytotoxicity of the viral nonstructural protein, NS1, which shows both enhanced levels of expression in transformed cells and preferential toxicity. 4 ,5 NS1 has multiple functions, including site-specific endonuclease activity, essential for replication of viral DNA, and transcriptional activation of the viral promoters. 1, 6 Several members of the rodent parvovirus group can efficiently infect human transformed cell lines. These viruses include parvovirus H1 of rats, the minute virus of mice (MVM), and the closely related parvovirus LuIII (natural host unknown) which we have previously used to construct recombinant vectors. [7] [8] [9] There have been isolated reports of attempts to use parvovirus H1 for treatment of cancer patients. 10, 11 The potential for therapeutic use of parvoviruses, based on their oncolytic properties, might be enhanced if NS1 expression and hence replication could be controlled by an appropriate drug. We therefore modified the P4 promoter of LuIII to try to impose regulation by a drugcontrolled mechanism. We chose to test the tetracycline regulatory system, based on the use of an artificial transactivator consisting of the prokaryotic repressor of the tetracycline operon, fused with the strong transactivation domain from the herpes simplex VP16 protein. 12 Expression of this chimeric transactivator in mammalian cells enables tight control by tetracycline derivatives over the transcription of foreign genes from a minimal promoter linked with operator sequences from the tetracycline operon. 12 In the original version of this regulatory system, the transactivator, tTA, was released from operator DNA by tetracycline so that the regulated gene was transcribed only in the absence of the drug. 12 More recently, a 'reverse transactivator' (rtTA) has been constructed from a mutagenized repressor that requires tetracycline for operator binding, thus providing positive response to the drug in mammalian cells. 13 Here, we report the construction of a recombinant LuIII genome with partial replacement of the P4 promoter by tetracycline operator and minimal promoter sequences. Unexpectedly, these sequences, when placed in the context of the parvovirus DNA, showed constitutive activity regardless of the presence of tTA or rtTA. We present results showing that this problem could be circumvented by the coexpression of a tetracycline-regulated repressor, 14 as opposed to a transactivator, thus enabling tetracycline control over parvovirus RF amplification.
Results
We previously described a recombinant of the rodent parvovirus, LuIII, which expressed luciferase, in a manner regulated by tetracycline, in tTA expressing cells transduced by the virus. 8 This recombinant genome, in the plasmid pTO-Lu-LUC, is shown in Figure 1 . To generate a conditionally replication-competent virus which should also be controllable by tetracycline, we introduced the same substitution of the P4 promoter region into a derivative of pGLu883, an infectious clone of the LuIII genome, 15 generating pTO-Lu (Figure 1 ). Transfection of pGLu883 into the permissive human cell line, NB324K, results in excision of the viral genome and abundant replication of linear, double-stranded replicative form DNA (RF). 7, 15 These processes require expression of the nonstructural protein, NS1, whose mRNA is transcribed from the viral left end promoter, P4. 1 We therefore expected that RF excision and amplification in cells transfected with pTO-Lu would be dependent on the presence of tTA, to transactivate NS1 expression from the substituted TO promoter. This transactivation should be abolished by addition of tetracycline. However, as shown in Figure  2 , similarly efficient RF amplification was seen in pTOLu transfected cells regardless of the presence of tTA or tetracycline.
This unexpected, constitutive RF production from pTO-Lu can be explained by the results shown in Figure  3 , where pTO-Lu-LUC was used as a reporter of activity of the TO promoter when placed adjacent to the LuIII left terminus (see Figure 1 ). As shown previously, 8 expression of this reporter was strongly activated by cotransfection with a tTA expression plasmid and this activation was abolished by tetracycline ( Figure 3 ). How- ever, similarly strong transactivation was observed when pTO-Lu-LUC was cotransfected with an expression plasmid for NS1 and this activation was unaffected by the presence of tetracycline (Figure 3 ). These results suggest that an initially low basal level of expression of NS1 from pTO-Lu may have sufficed to initiate a self-stimulatory loop that resulted in abundant NS1 production and consequent efficient RF amplification (Figure 2 ). This interpretation was further supported by the finding that luciferase expression from pTO-Lu-LUC was also activated by cotransfected pTO-Lu (Figure 4) .
Figure 2 Southern analysis of Hirt extracts from NB324K cells, prepared 39 h following electroporation with pTO-Lu
Since pTO-Lu was thus apparently capable of selfactivation, we considered the possibility that tetracycline control might be imposable by using a repression, as opposed to activation, mechanism. We tested this possibility using a tetracycline-controlled transcriptional repressor (TetR-KRAB) consisting of a fusion of the bacterial tetracycline repressor with the KRAB repression domain from Kox1, a human Krü ppel-type zinc finger protein.
14 It was previously shown that this fusion construct could repress transcription from a strong CMV promoter, placed adjacent to tetracycline operator sequences and that the repression was relieved by tetracycline.
14 Figure 4 shows results of cotransfecting an expression plasmid for TetR-KRAB together with pTOLu-LUC and pTO-Lu. TetR-KRAB expression abolished transactivation by pTO-Lu in the absence of tetracycline but had no effect in cells that were exposed to a low concentration of doxycycline (Figure 4) . Furthermore, as also shown in Figure 4 , the repressor could be used in combination with a tetracycline-dependent transactivator (the 'reverse' transactivator, rtTA 13 ) to achieve an even higher level of doxycycline control (150-fold) over transactivation of luciferase expression from pTO-Lu-LUC (Figure 4) .
We next examined whether the TetR-KRAB repressor would allow similar drug control over RF excision and amplification from transfected pTO-Lu. The results shown in Figure 5 demonstrate that this was the case. Hirt extracts were prepared at 28 or 50 h after transfection of NB324K cells with pTO-Lu, with or without cotransfection with the TetR-KRAB expression plasmid. In the absence of doxycycline, the latter repressed RF production to a low level ( Figure 5, tracks 3 
Discussion
In several of the major human cancers, including breast, prostate and melanoma, successful resection of the primary tumor is possible but patients frequently succumb to intractable metastatic disease. The possibility of thera- peutically exploiting virus infection of metastases, with subsequent viral replication and cytopathicity, is an attractive idea of long standing. 16 Parvoviruses are good candidates for this approach because of their small size, preference for replicating, malignantly transformed cells and well-documented oncolytic effects in experimental animals. 1, 3 These viruses are amenable to genetic manipulation as a possible means of targeting and enhancing their potential oncolytic properties in patients. A desirable goal, in terms of both efficacy and safety, would be to achieve controlled, conditional replication of the therapeutic virus using an appropriate drug. Our results demonstrating tetracycline control over amplification of parvovirus LuIII RF DNA represent a first step in this direction. The tetracycline system is attractive for this approach because it offers tight regulation of gene expression by low concentrations of clinically used tetracycline derivatives with well-defined pharmacology.
Our initial attempts to impose drug control over replication of LuIII were compromised by the transactivation properties of the essential viral nonstructural protein, NS1. This multifunctional protein strongly transactivates transcription of mRNAs encoding the capsid proteins from the viral promoter, P38, 1 but has been reported to affect the left-end promoter, P4, only relatively weakly. 17 We expected that our replacement of most of the P4 promoter by tetracycline operator sequences, linked with a minimal promoter, would render transcription dependent on the tTA transactivator. However, the resulting construct, pTO-Lu, did not show this dependence; this was apparently due to an initially low basal level of NS1 expression which then acted in a self-stimulatory manner. Since we observed strong NS1 transactivation of luciferase expression from pTO-Lu-LUC which lacked the entire viral coding sequences, this apparent selfstimulation by NS1 was probably mediated by the NS1 binding site in the viral left terminus. 18 Although this site is essential for viral DNA replication, and so could not be deleted or mutated, it is possible that further manipulation of the P4 region (eg of sequence content or spacing between the NS1 binding site and tetracycline operator sequences) might enable tTA control of transcription.
We found that tetracycline control over pTO-Lu could be imposed by an alternative means, using a chimeric repressor protein, TetR-KRAB, instead of a transactivator. 14 In the presence of this protein, we observed efficient RF amplification from transfected pTO-Lu only in the presence of doxycycline. In the absence of this drug, when TetR-KRAB was functional as a repressor by binding to the operator sequences, RF production was only minimal. Thus, under these conditions the binding of TetR-KRAB was evidently able to repress transactivation by NS1 bound to the adjacent parvoviral terminal DNA sequence. These results provide the first demonstration of ability to impose drug regulation on replication of a modified parvovirus genome. The TetR-KRAB has recently been used in a similar way to restrict DNA replication of an adenovirus vector. 19 Successful application of drug control over virus replication using this type of system requires that the relevant trans-acting molecule, whether a drug-controlled activator or repressor, be present in the infected cell. Packaging size constraints would preclude encoding such a protein within a replication-competent parvovirus genome retaining both the nonstructural and capsid-coding regions. However, the latter functions might be partitioned between two mutually dependent viruses, one of which could encode a transactivator or repressor. Such a parvovirus-based, drug-controlled binary system may hold promise for therapeutic targeting of metastases.
Materials and methods

Plasmid constructs
Standard cloning methods 20 were used to generate the constructs shown in Figure 1 . pTO-Lu-LUC has been described previously. 8 pTO-Lu was made as follows. The left end of the LuIII genome from pGLu883⌬Xba, 7 extending to the MluI site at nt 277, was subcloned into an intermediate plasmid and a BglII adapter oligonucleotide was then ligated between the StyI site at nt 144 and the NcoI site at nt 265 (which overlaps the initiation codon for the nonstructural proteins). A DNA fragment (0.48 kb BglII to BamHI) containing seven copies of the tetracycline operator, linked with a minimal CMV promoter, was isolated from a derivative of pUHC13-3 12 and was ligated into the BglII site of the adapter. The resulting, modified LuIII left end was then substituted as a PstI-MluI fragment for the left end in pGLu883 to generate pTO-Lu. Further details are available on request. pCMV-tetR-KRAB 14 was a gift from Dr U Deuschle, Hoffman-La Roche Ltd, Basel, Switzerland. To minimize the possible occurrence of deletions, Escherichia coli strain SURE (Stratagene, La Jolla, CA, USA) was used for propagation and isolation of plasmids containing the LuIII inverted terminal repeats. Other plasmids were grown in E. coli strain HB101. Plasmids were isolated by alkaline lysis and were purified by banding in CsCl in the presence of ethidium. 20 Cell culture and transfection by electroporation The SV40-transformed human kidney cell line, NB324K 21 (a gift from Dr P Tattersall, Yale University School of Medicine, New Haven, CT, USA) was maintained in either OptiMEM (Life Technologies, Gaithersburg, MD, USA) with 3.8% fetal bovine serum, or in RPMI1640 with either 10% NuSerum IV (Collaborative Biomedical Products; Becton Dickinson, Bedford, MA, USA) or 7.5% fetal bovine serum ('Tet System Approved'; Clontech, Palo Alto, CA, USA).
Electroporation used a capacitance discharge unit (IBI Gene Zapper, Eastman-Kodak, New Haven, CT, USA). NB324K cells were grown to 60-70% confluency, before being trypsinized and suspended with cold medium. Samples of cell suspension (0.8-1.0 × 10 7 cells/ml) were electroporated in complete medium 22 with the indicated amounts of plasmids, made up with a 'filler' plasmid (pUC18 or equivalent, lacking eukaryotic sequences) to total DNA concentration 50 g/ml. Voltage was set at 230 volts and the capacitance was set to give a time constant of approximately 30 ms (250 F or 500 F, respectively, for pulsing of 0.1 ml or 0.2 ml cell suspension).
Analysis of replicative form (RF) DNA amplification Excision and amplification of RF were analyzed by Hirt extraction of low molecular mass DNA, followed by gel electrophoresis and Southern blotting as described. 7 At the indicated times, the transfected cells were treated with DNaseI (to degrade residual plasmid) before Hirt extraction. The resulting low molecular mass nucleic acid samples were treated with RNaseA and with DpnI and were then electrophoresed in a 1% agarose gel, transferred to nylon and hybridized with a digoxigeninlabeled probe. 7 Assay of luciferase activity Cell extracts were prepared and assayed for luciferase activity using a commercial kit (Luciferase Assay System; Promega, Madison, WI, USA) and a model TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA).
